AZP-3601 SAD and MAD Study in Healthy Subjects and Subjects With Hypoparathyroidism
Status:
Recruiting
Trial end date:
2023-01-01
Target enrollment:
Participant gender:
Summary
This study is investigating the safety, tolerability, pharmacodynamics and pharmacokinetics
of AZP-3601 following single and repeated administration in both healthy volunteers and
patients with chronic hypoparathyroidism (cHP)
The protocol includes 3 parts:
- Part A: first-in-human single ascending dose (SAD) study in healthy volunteers
- Part B: multiple ascending dose (MAD) study with 2 weeks of treatment in healthy
volunteers
- Part C: open-label MAD study with a total treatment duration of 3 months in patients
with cHP.